مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

39
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

49
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

Effi cacy of Intracavernosal Injections of 50-Unit Versus 100-Unit Doses of AbobotulinumtoxinA (Masport® ) in Vasculogenic Erectile Dysfunction with Phosphodiesterase Type 5 Inhibitors Resistant

Pages

  0-0

Abstract

 Background: We aimed to evaluate the safety and effi cacy of 50-unit dose against 100-unit dose of intracavernosal injection (ICI) of AbobotulinumtoxinA (BTX-A) (Masport® ) in patients with vascular Erectile Dysfunction (ED) resistant to fi rst-line therapies, including phosphodiesterase type 5 inhibitors (PDE5I). Methods: In this double-blind randomized controlled trial (RCT), 40 patients with ED resistant to PDE5I were randomly divided into two groups: ICI of a single dose of Masport® 50 units and single dose of 100 units. Peak systolic velocity (PSV) confi rmed arterial insuffi ciency vascular disorder. For all patients, International Index of Erectile Function (IIEF), Sexual Health Inventory for Men (SHIM), and Erection Hardness Score (EHS) questionnaires were completed. Six weeks after the treatment, the subjects were reexamined. Results: Our results showed an acceptable clinical effi cacy and safety of ICI of Masport® six weeks after injection. No systemic complications in patients were seen. Three patients complained of brief penile pain shortly after injection, but there were no other local complications. The increase in mean PSV in the 100-unit group due to treatment was signifi cant (P-value < 0. 0001). Also, there was a signifi cant diff erence between the two groups of 50-and 100-unit (P-value < 0. 0001). In addition, the increase in mean IIEF-EF, SHIM score, and EHS due to treatment was signifi cant between the two groups. For the 100-unit group, P-value < 0. 0001 and the diff erence between the two groups was also signifi cant (P-value < 0. 0001), which indicated a better response to treatment in the 100-unit group. The mean increase of IIEF score (EF domain) was 4. 3 (mean IIEF: 9. 4 and 13. 7 after and before, respectively) in the 100-unit group and (mean IIEF: 8. 1 and 9. 1 after and before, respectively) in the 50-unit group. Conclusions: The results of this study showed that ICI of AbobotulinumtoxinA, especially at a dose of 100 units, in patients with refractory vasculogenic ED is safe and eff ective in improving sexual function and ultrasound indices.

Cites

  • No record.
  • References

  • No record.
  • Cite

    APA: Copy

    MORADI, SAJAD, KHAZAELI, DINYAR, DADFAR, MOHAMMADREZA, & Bakhtiari, Nima. (2022). Effi cacy of Intracavernosal Injections of 50-Unit Versus 100-Unit Doses of AbobotulinumtoxinA (Masport® ) in Vasculogenic Erectile Dysfunction with Phosphodiesterase Type 5 Inhibitors Resistant. THE JOURNAL OF NEPHRO-UROLOGY MONTHLY, 14(1), 0-0. SID. https://sid.ir/paper/984342/en

    Vancouver: Copy

    MORADI SAJAD, KHAZAELI DINYAR, DADFAR MOHAMMADREZA, Bakhtiari Nima. Effi cacy of Intracavernosal Injections of 50-Unit Versus 100-Unit Doses of AbobotulinumtoxinA (Masport® ) in Vasculogenic Erectile Dysfunction with Phosphodiesterase Type 5 Inhibitors Resistant. THE JOURNAL OF NEPHRO-UROLOGY MONTHLY[Internet]. 2022;14(1):0-0. Available from: https://sid.ir/paper/984342/en

    IEEE: Copy

    SAJAD MORADI, DINYAR KHAZAELI, MOHAMMADREZA DADFAR, and Nima Bakhtiari, “Effi cacy of Intracavernosal Injections of 50-Unit Versus 100-Unit Doses of AbobotulinumtoxinA (Masport® ) in Vasculogenic Erectile Dysfunction with Phosphodiesterase Type 5 Inhibitors Resistant,” THE JOURNAL OF NEPHRO-UROLOGY MONTHLY, vol. 14, no. 1, pp. 0–0, 2022, [Online]. Available: https://sid.ir/paper/984342/en

    Related Journal Papers

  • No record.
  • Related Seminar Papers

  • No record.
  • Related Plans

  • No record.
  • Recommended Workshops






    Move to top
    telegram sharing button
    whatsapp sharing button
    linkedin sharing button
    twitter sharing button
    email sharing button
    email sharing button
    email sharing button
    sharethis sharing button